Azacitidine is the first-line therapeutic option for myelodysplastic syndrome (MDS). This report describes a case of MDS in a patient who developed fatal acute interstitial pneumonitis (AIP) after the first seven-day course of intravenous azacitidine (75 mg/m 2 /day) treatment. A review of previous and present studies of azacitidine-associated AIP suggests that azacitidine may cause life-threatening AIP during or after the first seven-day course of treatment, with pyrexia commonly preceding AIP. Although the non-hematologic adverse events associated with azacitidine are generally relatively mild, further accumulation of evidence may help to make an earlier diagnosis of azacitidine-associated AIP.
Introduction
Azacitidine, the first-in-class clinically available DNA hypomethylating agent, has been used as the first-line treatment for myelodysplastic syndrome (MDS) since a clinical study demonstrated the superiority of azacitidine over best supportive care and conventional chemotherapy incorporating cytarabine and anthracycline (1, 2) . Although therapy with azacitidine is commonly well tolerated and can be administered in the outpatient setting, safety data for azacitidine indicate the occurrence of various types of common hematologic and non-hematologic chemotherapy-associated adverse events. The latter include relatively frequent gastrointestinal events, such as nausea, vomiting, constipation or diarrhea, pyrexia, fatigue, mucositis, local injection site reactions, etc., as well as rare but severe adverse events, such as coma (2) (3) (4) . Although not mentioned in reports of large clinical trials among both Caucasian and Asian patients (2, 3, 5) , several recent studies have reported the development of noninfectious acute interstitial pneumonitis (AIP) in association with azacitidine treatment in MDS patients (6) (7) (8) (9) (10) . Although this event is extremely rare, further accumulation of evidence may help to make an earlier diagnosis and improve decision making regarding the optimal treatment of azacitidine-associated AIP. This article describes the case of a patient with MDS whose disease was complicated by fatal AIP during the first course of azacitidine treatment. In addition, we review previous case reports to identify the clinicopathologic characteristics of azacitidineassociated AIP in MDS patients.
Case Report
A 72-year-old man came to our hospital complaining of general fatigue and dyspnea on exertion. He had a history of coronary arterial stenosis that had been successfully treated with interventional catheterization, and a systemic examination performed on admission excluded a diagnosis of symptomatic heart failure. The results of a peripheral blood examination showed pancytopenia with a white blood cell count of 2.6×10 9 /L containing 34% neutrophils and 2% abnormal myeloblasts, with a hemoglobin level of 8.2 g/dL and a platelet count of 26×10 9 /L. Other laboratory findings on admission are summarized in Table 1 . A bone marrow analysis showed hypocellularity (23×10 9 /L) with trilineage dysplastic features and an abnormal increase in myeloblasts, accounting for 6.2% of all nucleated cells. A karyotype /day) intravenously for seven days and subsequently developed moderate pyrexia up to 37.5 from day 3 to 5 of treatment. His temperature further rose to 38.0 on day 6 without any signs of an infectious disease. During this period, his other vital signs were normal, including an oxygen saturation level between 96% and 98% on room air. On day 7, he began to complain of dyspnea, a dry cough and a small amount of bloody sputum and wheezing associated with progressive hypoxic respiratory failure requiring oxygen supplementation. At that time, a chest X-ray showed patchy airspace disease in the right upper field and bilateral lower fields (Fig. 1b) . A computed tomography scan demonstrated areas of interstitial opacity and ground glass shadowing in the right upper field and bilateral mid-to-lower fields ( Fig. 2a-c) , as well as mediastinal lymph node swelling and a small amount of bilateral pleural effusion (Fig. 2d) . Treatment with broad-spectrum antibiotics and antifungal agents was initiated, although no infectious agents were identified on advanced microbiologic or virologic examinations, including microbacterial and mycobacterial cultures of the sputum and blood and tests for cytomegalovirus antigenemia, Aspergillus and Cryptococcus neoformans antigens, β-D-glucan for fungal and Pneumocystis jirovecii infection and the procalcitonin level. While the serum C-reactive protein and surfactant protein (SP)-A levels had increased to 10.22 mg/dL (normal range: 0.00-0.20 mg/dL) and 63.8 ng/mL (0.0-43.7 ng/mL), respectively, the serum sialylated carbohydrate antigen (KL-6), SP-A and immunoglobulin E levels remained within the normal ranges. The patient's symptoms persisted for the next four days without any improvements, and a chest X-ray showed worsening of the patchy and reticulogranular shadowing (Fig. 1d) . Based on the Naranjo algorithm for assessing the causality of adverse drug reactions (11), we made a probable diagnosis of azacitidineassociated AIP. Indeed, the patient's subsequent clinical course, including migrating abnormal pulmonary shadowing (Fig. 1a-h ) without laboratory results indicating infectious disease or a response to various types of antimicrobial agents, further supported the diagnosis of drug-induced AIP. The patient was therefore treated with intravenous methylprednisolone (500 mg) for four days, followed by high-dose corticosteroid therapy in combination with sulfamethoxazole trimethoprim, vancomycin and micafungin. His respiratory condition transiently improved for two days, although it worsened again on day 14 after the start of azacitidine treat- ment. Although the patient's respiratory failure progressed to an oxygen saturation of 70%, even with maximum oxygen supplementation, he and his family refused mechanical ventilation. Despite the administration of intensive treatment with high-dose corticosteroids, antibiotics and antifungal agents supported by maximum oxygen supplementation for the next four days under sedation with low doses of morphine and midazolam, the patient died of multiorgan failure on day 19 after the initiation of azacitidine treatment.
Discussion
Many cytotoxic agents utilized in anticancer therapy can cause AIP, which may be life-threatening (12, 13) . The management of AIP requires a quick diagnosis and prompt treatment, although obtaining a definitive diagnosis of druginduced AIP is not always straightforward, as it requires the physician to rule out other causative factors for lung disease, such as infectious diseases, in addition to performing a pathological assessment if possible. Because patients with MDS are generally highly immunocompromised and performing a lung biopsy is difficult due to their poor general condition and high risk of hemorrhage as a result of thrombocytopenia, as observed in the present case, it is difficult to make a quick and correct differential diagnosis between drug-induced AIP and infectious disease. In view of the lack of sufficient diagnostic tools, the accumulation of clinical findings in patients with drug-induced AIP can be expected to yield important information for daily clinical practice.
As far as we were able to determine based on a search of the English literature, there are six reports of MDS patients, including the present patient, with azacitidine-associated AIP (Table 2 ) (6-10). An antemortem lung biopsy was performed in only one patient, and the diagnosis of AIP in each case was primarily made based on radiological findings consistent with a diagnosis of organizing pneumonia or interstitial pneumonia, negative results for infectious agents and the lack of response to antimicrobial agents. The pulmonary characteristics varied among the patients, although the lesions were generally bilateral and diffuse, and a small amount of pleural effusion was common. The onset of AIP was primarily observed during or after the first course of azacitidine treatment, and the administration of a second course of azacitidine further worsened the AIP in two patients whose symptoms were relatively mild during the first course of therapy. Most patients presented with pyrexia prior to the onset of AIP and subsequently developed AIP within one week. Because moderate pyrexia is relatively common during the course of treatment with azacitidine (2-5), physicians must pay careful attention to the respiratory symptoms of febrile patients, even those without signs of infectious disease, during and after the first course of azacitidine treatment, so as not to overlook the signs of AIP. Although relevant information remains limited, the degree of pulmonary damage caused by azacitidine-associated AIP is likely to be severe. Two patients, including the present patient, died of azacitidine-associated AIP (7), while transient mechanical ventilation was required in two of the four patients who survived (9, 10) . Although there was no diagnostically relevant pathological information regarding AIP in the present case, methylprednisolone pulse therapy (500 mg/body × four days) was started on day 5 (i.e., day 11 after the initiation of azacitidine treatment) based on the radiologic diagnosis of interstitial pneumonitis. It is conceivable that providing pharmacological treatment much earlier with high-dose corticosteroid therapy may have rescued our patient.
In conclusion, we herein reported a case of azacitidineassociated AIP. Because the mechanism underlying the development of azacitidine-associated AIP remains unknown and AIP is an extremely rare adverse event associated with azacitidine treatment, larger studies including such factors as genetic background factors are needed to improve the ability to identify high-risk patients.
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